Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Jun 03, 2022 11:11am
298 Views
Post# 34729611

RE:RE:RE:RE:RE:RE:RE:RE:BMS to buy Turning Point Therapeutics for 4.1B$US

RE:RE:RE:RE:RE:RE:RE:RE:BMS to buy Turning Point Therapeutics for 4.1B$USYep, not a bad number at all. If I can do a simple calculation, know Pharma can do even better number crunching. As can Kristina. And everyone knows NMIBC is just a small sliver of TLT's potential. I doubt we will get any less that $3B US as an early buyout offer. 

LaserStock29 wrote:
Legit62 wrote: Thats not a bad number, plus we have other indications in the works which could drive that higher


Only get paid for the science that's matured and developed License out rights for other indications = bigger cash upfront NMIBC is probably 2b -3broughly for TLD 1433 Then licensing Ruthenium with ACT for the other indications by Dr.Kaspler 5 of em Lung, brain, head neck, cervical and colon. Get it done by 1Q 2023 and stop f'ing around


<< Previous
Bullboard Posts
Next >>